Aage dekho, Shaily Engineering Plastics ne Q3 FY26 mein kya kamaal kiya hai! Inka total revenue 27% saal-dar-saal badh kar ₹251 crore ho gaya. Iske peeche ka asli hero hai inka healthcare segment, jo 139% bhaga aur ab company ke total revenue ka 42% hissa ban gaya, matlab ₹104 crore. Socho, pura healthcare pe focus chal gaya hai!
Lekin yeh sab sirf achhi khabar nahi hai. Inka purana consumer business thoda dhakka kha gaya, revenue 13% gir kar ₹123 crore ho gaya. Europe aur US mein demand kam hone ki wajah se aisa hua hai. Toh ek taraf boom, doosri taraf thanda.
Financials ki baat karein toh EBITDA toh 43% chadh kar ₹66 crore ho gaya, aur margins bhi mast 26.5% ho gaye. Toh profit toh badha hai boss!
Ab sabse badi khabar - company ₹300-350 crore daal rahi hai UAE mein ek naya plant lagane mein. Yeh plant saal mein 75 million pen injectors banayega. Isse company ki global capacity lagbhag double ho jayegi, aur yeh plant Q4 FY'28 tak ready hoga.
India mein bhi July 2026 tak do naye high-speed lines aa rahe hain. Aur future mein yeh log consumer electronics aur semiconductor casing mein bhi ghusne ka soch rahe hain.
Par investors ke kuch sawaal bhi hain. Ek toh yeh naye high-speed lines mein internal testing mein 30% rejection rate dikha hai, matlab operational efficiency par sawaal hai. Aur bade pen injector deals mein 10-15% price erosion bhi dekhne ko mil raha hai, jisse margins pe farak pad sakta hai. Management keh raha hai ki yeh sab manage ho jayega, but abhi toh yeh chinta ka vishay hai.
Toh main risks kya hain? Consumer business ka girna, naye lines ki efficiency, aur woh price erosion ka pressure. Plus, woh UAE plant banane ka ek reason yeh bhi tha ki pichli baar ek client ne manufacturing scalability issues ke karan contract cancel kar diya tha. Toh business continuity bhi ek big factor hai.